Senior Director of Discovery Technologies
AssayQuant Technologies Inc.
Earl brings over 25 years of expertise in biochemistry, biophysics, and enzymology across multiple therapeutic areas to AssayQuant Tehcnologies. He has held research and leadership roles for companies like SmithKline Beecham, GlaxoSmithKline, OSI Pharmaceuticals, and numerous innovative biotechnology companies. He has explored hundreds of drug targets at the early end of the pipeline and has driven dozens of projects into and through screening and hit-to-lead activities. Over the last decade, his enzymology experience has deepened with a focus on time-dependent and irreversible inhibition, protein-protein interaction inhibitors, and three-body biophysics problems, with over half of the enzymes he targeted being kinases.